<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132736">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373840</url>
  </required_header>
  <id_info>
    <org_study_id>201102481</org_study_id>
    <nct_id>NCT01373840</nct_id>
  </id_info>
  <brief_title>Role of Dopamine Receptors in Primary Focal Dystonias</brief_title>
  <official_title>Role of Dopamine Receptors in Primary Focal Dystonias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dystonia is a disabling movement disorder characterized by repetitive patterned or sustained
      muscle contractions causing twisting or abnormal postures that may afflict 250,000 people in
      the U.S. While the pathophysiology of dystonia remains uncertain the treatment is rather
      rudimentary. A better understanding of neural mechanisms of dystonias is not only an
      invaluable prerequisite for developing better treatment options but also a step toward
      better understanding of the complex network of basal ganglia. In this study I will
      investigate if there is any difference between the dopamine receptors and dopamine in people
      with dystonia and healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <condition>Focal Dystonias</condition>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with focal dystonias</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any healthy control or patient with primary focal dystonia or arm or face.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;20

          -  Male or Female

          -  Any race or ethnicity

          -  Primary focal dystonia (arm or cranial)

          -  Ability to give informed consent

        Exclusion criteria:

          -  Family history of dystonia

          -  Pregnancy (confirmed with negative urine pregnancy test in women of child bearing
             potential), breastfeeding

          -  Exposure to radiation therapy

          -  Any MRI contraindications such as foreign metallic implants, pacemaker, and aneurysm
             clip etc.

          -  History of cardiac disease, uncontrolled hypertension, abnormal EKG during screening
             phase

          -  History of exposure to any drugs affecting dopaminergic systems within the last 6
             months (e.g. dopamine receptor blocking agents, cocaine, amphetamine, tetrabenazine,
             reserpine, L-dopa, dopamine agonists, as they might affect the dopamine receptor
             binding or endogenous dopamine).

          -  Active depression (Beck Depression Inventory_II &gt;14)

          -  Cognitive impairment (Mini-Mental State Score &lt;27)

          -  CNS active medications such as gabapentin or narcotics, muscle relaxants which might
             be given for pain in the 3 days prior to study

          -  History of stroke, seizure, cerebral palsy, generalized dystonia, parkinsonism,
             inability to hold head still during the scanning time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morvarid Karimi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pratt Stacey</last_name>
    <phone>314-747-5916</phone>
    <email>pratts@npg.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacey Pratt</last_name>
      <phone>314-747-5916</phone>
      <email>pratts@npg.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Morvarid Karimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 2, 2011</lastchanged_date>
  <firstreceived_date>June 10, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Morvarid Karimi, MD</name_title>
    <organization>Washington University</organization>
  </responsible_party>
  <keyword>focal</keyword>
  <keyword>dystonia</keyword>
  <keyword>dopamine</keyword>
  <keyword>receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
